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Abstract
Background: Hepatitis C virus (HCV) coinfection was reported to negatively affect HIV disease and HIV infection
has a deleterious effect on HCV-related liver disease. However, despite common occurrence of HCV/HIV coinfection
little is known about the mechanisms of interactions between the two viruses.
Methods: We studied CD4+ and CD8+ T cell and CD19+ B cell apoptosis in 104 HIV-positive patients (56 were also
HCV-positive) and in 22 HCV/HIV-coinfected patients treated for chronic hepatitis C with pegylated interferon and
ribavirin. We also analyzed HCV/HIV coinfection in a Daudi B-cell line expressing CD4 and susceptible to both HCV
and HIV infection. Apoptosis was measured by AnnexinV staining.
Results: HCV/HIV coinfected patients had lower CD4+ and CD8+ T cell apoptosis and higher CD19+ B cell
apoptosis than those with HIV monoinfection. Furthermore, anti-HCV treatment of HCV/HIV coinfected patients was
followed by an increase of CD4+ and CD8+ T cell apoptosis and a decrease of CD19+ B cell apoptosis. In the Daudi
CD4+ cell line, presence of HCV infection facilitated HIV replication, however, decreased the rate of HIV-related cell
death.
Conclusion: In HCV/HIV coinfected patients T-cells were found to be destroyed at a slower rate than in HIV
monoinfected patients. These results suggest that HCV is a molecular-level determinant in HIV disease.
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Background
Hepatitis C virus (HCV) coinfection is very common among
HIV-positive patients. Today up to 30% of all HIV-infected
patients and as many as 85% of HIV-infected intravenous drug
users (IDUs) are also HCV-positive [1]. HIV infection has a
deleterious effect on HCV-related liver disease and due to
falling AIDS mortality rates in the HAART era, liver disease has
become the leading cause of death among HIV-infected
patients [2–4]. These negative effects could be attributed to
increased HCV replication in the setting of HIV-related
immunosuppression, and some studies found close association
between low CD4 cell count and the development of fibrosis
and cirrhosis among coinfected patients [5,6]. However, there
is some evidence that HIV may increase HCV replication more
directly. Thus, primary HIV infection among HCV-positive
patients is accompanied by a burst of HCV replication [7] and
HCV RNA serum loads are more closely correlated with HIV
RNA levels than with CD4+ cells [8]. It was also reported that
concomitant or antecedent HIV infection may facilitate HCV
replication in vitro [9]. Accelerated liver disease in HIV/HCV
coinfection may also be the result of direct viral interactions as
it was found that envelope proteins of both viruses may act
collaboratively in injuring uninfected hepatocytes through an
‘innocent bystander’ mechanism [10].
However, HCV-HIV interactions are bidirectional as there is
emerging evidence that HCV could negatively affect HIV
disease. In several cohort studies HIV/HCV co-infected
patients were found to be more likely to progress to AIDS and
to have slower CD4 cell recovery on HAART, than those
infected with HIV only [11–13].
Despite common occurrence of HCV/HIV coinfection, little is
known about biological interactions between the two viruses.
The current study provides evidence that HCV coinfection may
affect HIV-related cell death both in vivo and in vitro.
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Methods
Ethics Statement
The study was assessed and approved by the Internal
Review Board at the Warsaw Medical University (ref No KBO/
1/010) and each patient provided written consent.
Patients
Two different groups of patients were studied. The first was
composed of consecutive HIV-positive patients presenting for
clinical outpatient care at the Municipal Hospital for Infectious
Diseases, Warsaw, Poland. The inclusion criteria were: age
above 18 years, willingness to participate in the study, and no
advanced HIV disease (CD4+ cell count > 200 per cubic
millimeter). Altogether, 56 were HCV-infected (anti-HCV and
HCV RNA positive), and 48 patients were anti-HCV negative.
Forty-five patients were on HAART and 41 had a history of
intravenous drug use (IDU).
The second group was composed of 22 HIV/HCV-coinfected
patients undergoing antiviral therapy for chronic hepatitis C.
Treatment protocol consisted of Pegylated Interferon
(Pegintron; Schering Plough) 1.5 µg/kg weekly and Ribavirin
(Rebetol; Schering Plough) 800 mg/day for genotype 3 and
1000 mg/day for genotypes 1 and 4. All had compensated liver
disease.
HIV RNA in serum was quantified by ABBOTT, Real Time
PCR HIV CE (Abbott Molecular Inc., Des Plaines, IL); HCV
RNA was quantified by ABBOTT, Real Time PCR HCV CE
(Abbott Molecular, Inc).
Apoptosis Assay of patients’ cells
PBMCs were isolated from blood by centrifugation over
density gradient. Cells were washed 3 times with PBS (pH 7.4),
suspended in RPMI 1640 medium containing 10% FBS, and
incubated in plastic 6-well cell culture dish (Costar), at a final
concentration of 106 cells/ml. After incubation at 37 °C for 24
hours, CD4+, CD8+ and CD19+ cells were assessed for their
sensitivity to spontaneous apoptosis by annexin V binding.
Accordingly, cultured cells were divided into 3 parts and double
stained with a fluorescein isothiocyanate-conjugated
monoclonal antibody to annexin V (Annexin V kit, BD) and one
of the phycoerythrin-conjugated monoclonal antibodies to CD4,
CD8, and CD19 (BD Sciences). Cells were washed and fixed
according to manufacturer’s procedure and immediately
analyzed on a FACScalibur flow cytometer using Cell Quest
software. For each sample, 104 events were acquired.
Propidium iodide (PI) positive cells were excluded from the
analysis to differentiate between apoptotic and dead cells.
Cell Line
Daudi-CD4+ cells, B-cell line transduced to express CD4,
was a kind gift of Dr. Olivier Schwartz [14]. Daudi cells were
chosen since they are susceptible to HCV infection in vitro [15]
and B cells are commonly infected in vivo [16]. This line was
maintained in RPMI-1640 supplemented with 10% fetal bovine
serum (FBS). Sera used for in vitro infection experiments were
collected from 7 chronic hepatitis C patients infected with
genotype 1b. Viral loads were: P1 = 2.2 x 106 IU/ml; P2 = 1.8 x
106 IU/ml; P3 = 5 x 105 IU/ml; P4 = 8.8 x 105 IU/ml; P5 = 6.0 x
105 IU/ml; 1W = 1.3 x 107 IU/ml; 5W = 1.5 x 108 IU/ml. Control
sera (N1-N5) were collected from healthy donors and were
negative for anti-HCV, anti-HIV, anti-HBc, and HGV RNA.
Viral infections
Cells were split 24 hours prior to infection (Day -1). On Day
0, cells were counted, pelleted, and resuspended at a density
of 5 x 105 cells per ml in RPMI-1640 (10% FBS). Cells were
then either infected with pNL4-3 (gift of K.T. Jeang, NIH) or
mock infected for two hours at 37°C. Following the incubation,
cells were pelleted, washed in complete RPMI-1640, and
resuspended at a density of 5 x 105 cells per ml. For
incubations with patient serum, cells were pelleted (Day 1),
washed with RPMI-1640 containing no serum, and then
incubated with RPMI-1640 containing 10% human HCV-
positive serum, or with RPMI-1640 containing 10% human
HCV-negative serum, or with medium containing only 10%
FBS. The infection was done at 37°C for 4 hours. Cells were
then pelleted, washed in RPMI-1640 (no serum) and
resuspended in complete RPMI-1640 plus 10% FBS.
Cells were counted each day beginning with Day 2, pelleted
(supernatant was removed and set aside), and resuspended at
a density of 5 x 105 cells per ml in medium comprised of equal
parts set-aside supernatant (to maintain HIV presence) and
fresh medium. Samples of supernatants were stored at -20° for
later use in HIV assays.
Reverse Transcriptase (RT) Assay
HIV was quantitated by RT assay as previously described
[17]: briefly, 10 µl supernatant was added to 40 µl cocktail (50
mM Tris Cl, pH 7.8, 63 mM KCl, 4.2 mM MgCl2, 0.08% Nonidet
P-40, 0.85 mM EDTA, 4.2 µg/ml polyA, 0.13 µg/ml oligo dT,
4mM DTT, 2 µl/ml [32P]TTP) and incubated for 2 hours at 37°C;
5 µl of the reaction mix was spotted onto DEAE paper, fixed 2x
in 2X SCC for 30 minutes, and placed on x-ray film. Arbitrary
units were quantitated by densitometry reading of the film with
Image Quant 5.2 software (Bio-Rad).
Apoptosis Assay of Daudi cells
To measure apoptosis, 2 x 106 cells were pelleted, washed
2X in PBS, resuspended in binding buffer (BD Sciences), and
stained with AnnexinV-FITC and propidium iodide. Following
staining, cells were washed 2X in binding buffer, resuspended
in 4% paraformaldehyde (Electron Microscopy Sciences) in
PBS, and fixation was continued for 2-3 hours. Data was
captured with a Becton Dickinson FACScan, and analyzed with
CellQuest software (BD, Mountain View). For each sample, 104
events were acquired.
Statistical Analysis
Continuous variables were compared with Mann-Whitney U
test. Spearman’s coefficient was used to calculate correlations.
P ≤ 0.05 was considered to be statistically significant.
Apoptosis in HIV-HCV Coinfection
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Results
Apoptosis in HCV/HIV coinfected patients
We analyzed 104 consecutive HIV-positive patients: 56 were
HCV positive and 48 patients were anti-HCV negative. Some
characteristics of these patients are presented in Table 1.
Analysis of flow cytometry data revealed that among HIV/
HCV-coinfected patients, CD4+ and CD8+ T cell apoptosis
(Annexin V positive, PI negative) was lower than in patients
infected with HIV only (Table 1). In the case of CD19+ cells,
apoptosis was higher among dually-infected patients, although
this difference did not reach statistical significance. There was
no statistically significant correlation between CD4+ cell count
or HIV RNA load and CD4+, CD8+, or CD19+ apoptosis in
either HCV-positive or HCV-negative group. Similarly, there
was no correlation between the HCV RNA load in serum and
apoptosis in any of the analyzed cell populations.
While both groups did not differ with respect to CD4+ cell
count, HIV viral load, or the number of patients on HAART,
HIV/HCV-coinfected patients were significantly younger and
most were IDUs, whereas among HIV-monoinfected patients
history of IDU was rare. Because of the skewed distribution of
IDU among our patients, statistical adjustment for this factor
was not possible.
To mitigate the effect of the above confounding factors, we
studied a group of HIV/HCV-coinfected patients undergoing
treatment for chronic hepatitis C. We hypothesized that if HCV
infection was indeed inhibitory to HIV-related apoptosis, drug-
induced inhibition of HCV replication would be followed by
subsequent increase in the level of apoptosis. Some basic
characteristics of these patients are presented in Table 2. All
patients had history of IDU but were required to remain
abstinent for at least 6 months prior to the study. Three were
on methadone treatment, 6 had abused alcohol, but were
abstinent for 6 months or longer. The most common infecting
genotype was type 1b found in 8 patients, followed by
genotypes 3 and 4c/4d, which were found in 6 and 7 patients,
respectively. In one patient the genotype was identified as 1a.
Apoptosis was analyzed right before the initiation of
treatment and at 3-4 weeks. In 16 patients a third analysis was
done 6-8 weeks from the beginning of treatment. As seen in
Figure 1, initiation of treatment resulted in an increase in
apoptosis of CD4+ and CD8+ cells, while apoptosis of CD19+
cells decreased. Furthermore, drop in HCV RNA load
correlated with increase in apoptosis of CD4+ (r=0.66; p<
0.001) and CD8+ cells (r=0.51; p=0.016).
Apoptosis in Daudi CD4+ cells
We first sought to determine if incubation with HCV-positive
patient serum would have any effect on HIV particle production.
We cultured cells in the absence of viral infection, or infected
with HIV only, or infected with HIV followed by incubation with
HCV-negative patient serum, or infected with HIV followed by
incubation with HCV-positive patient serum. After exposure to
HCV-positive sera, HCV RNA positive and negative strands
were detectable in cells, which is compatible with the presence
of replication. However, the viral load was small - positive HCV
RNA strand was present at a concentration of 10(2) -10(3) per
10(6) cells, while the negative strand was ≤10(2) per 10(6)
cells. We compared the RT activity of supernatant from day 3,
6, 9, and 12 for cells incubated with each of the 5 HCV-positive
Table 2. Characteristics of 22 HIV/HCV coinfected patients
undergoing treatment with Pegylated interferon and
Ribavirin.
Parameter HIV+/HCV+ N=22
Age (yrs) 34.5 (22-56)
Gender F (%) 7 (32)
History of IDU (%) 22 (100)
Alcohol abuse (%) 6 (27)
ALT (IU/L) 62 (21-522)
HAART therapy (%) 3 (14)
HCV RNA in plasma (log10) 5.87 (3.16-7.03)
CD4 counts (cells/mm3) 467 (324-885)
Genotype 1a (%)  1 (5)
1b  8 (36)
3a  7 (32)
4c/4d  6 (27)
Continuous variables are reported as median (range)
doi: 10.1371/journal.pone.0075921.t002
Table 1. Characteristics of HIV/HCV coinfected patients as compared to HIV-monoinfected patients
Characteristic HIV+/HCV+ (n = 56) HIV+/HCV- (n = 48) Statistical Significance
Age (yrs) 36.0 ± 1.3 43.6 ± 1.6 < 0.001
No. (%) of Women 15 (27) 4 (8) 0.021
No. (%) History of IDU 40 (71) 1 (2) < 0.001
ALT (IU/L) 71.8 ± 6.5 60.2 ± 14.9 < 0.001
No. (%) on HAART 23 (41) 22 (46) NS
HIV RNA in serum, IU/ml (x 104) 2.38 ±0.62 0.99 ± 0.32 NS
CD4+ cell count (cells/mm3) 430 ± 29 464 ± 37 NS
% of apoptotic CD4+ T cells 5.45 ± 0.59 7.35 ± 0.76 0.039
% of apoptotic CD8+ T cells 12.07 ± 1.0 15.46 ± 1.2 0.049
% of apoptotic CD19+ cells 7.41 ± 1.4 4.80 ± 0.7 0.22
Continuous variables are reported as mean ± SEM; Apoptotic cells are those binding to Annexin V
Apoptosis in HIV-HCV Coinfection
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sera and each of the 5 HCV-negative sera (Figure 2A and 2B).
Though there was sample-to-sample variation, the average of
the RT activity from cells incubated with HCV-positive serum
was higher than the average of the RT activity in cells
incubated with HCV-negative serum at days 6, 9, and 12 post
infection (Figure 2B). This could indicate that exposure to HCV-
positive sera facilitates HIV replication; however, it could also
indicate that sera from hepatitis C patients extend viability of
HIV-infected cells. In support of the latter possibility came our
observation that supernatant from cells infected with HIV and
cultured with HCV-positive serum continued to demonstrate RT
activity for 1-2 days longer than did the supernatant from cells
infected with HIV only or with HIV followed by incubation with
HCV-negative serum (data not shown).
To explore this possibility, we measured cell viability of HIV-
infected cells incubated with HCV-positive patient serum and
compared it to that of HIV-infected cells incubated with HCV-
negative patient serum (Figure 2C). Cell viability was measured
by staining cells with AnnexinV-FITC (AV) and propidium iodide
(PI): viable cells were negative for both AV and PI. The results
of this assay showed that cells incubated with either HCV-
positive or HCV-negative serum with or without HIV infection
remained similarly viable till Day 3. However, by day 5, only
20% of the HIV-infected cells incubated with HCV-negative
serum remained viable, while 50% of the HIV-infected cells
incubated with HCV-positive serum were still viable (Figure
2C). This suggested that the HCV-positive serum was inhibiting
apoptosis in HIV-infected cells, and that this protection was not
conferred by serum from healthy individuals.
In the HIV-infected Daudi-CD4 cells, loss of viability had
occurred rapidly during a 24-hour period between cell harvests;
to track the changes in viability we assayed for apoptosis every
8 hours from Day 4 to Day 6 plus 16 hours (Figure 3 shows
results from Day 5 + 8 hours to Day 6 + 16 hours). We tested
effects of serum from two different HCV-positive patients (1W
and 5W). To slow the rate of apoptosis, we reduced the
infection dose of HIV to 2x104 cpm and cell concentration was
adjusted to 105 per ml every 24 hours until day 5. This lower
cell concentration was used to prevent early media depletion,
which could affect cell viability. Uninfected cells that were not
incubated with patient serum at all were viable throughout the
experiment (Figure 3). Uninfected cells incubated with either
HCV-positive or HCV-negative serum alone also remained
70-80% viable through Day 6 plus 16 hours. When cells were
infected with HIV prior to incubation with patient serum, there
was not only loss of viability, but there was also an increase in
the number of cells in the “final” stage of apoptosis. The results
in Figure 3 are nearly identical to what was seen in Figure 2C:
HIV-infected cells incubated with HCV-positive serum 5W
remained 50% viable, while HIV-infected cells incubated with
Figure 1.  Changes in CD4+, CD8+ and CD19+ cells apoptosis in 22 HCV/HIV coinfected patients treated with pegylated
interferon and ribavirin.  Apoptosis was assessed by Annexin V staining and flow cytometry. Patients were tested right before
initiation of treatment and after 3-4 weeks. In 16 patients testing was repeated 6-8 weeks from the initiation of treatment. Apoptosis
of CD4+ and CD8+ T cells increased during therapy, while apoptosis of CD19+ B cells decreased.
doi: 10.1371/journal.pone.0075921.g001
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HCV-negative serum were only about 20% viable. The results
of HCV-positive serum 1W were even more dramatic in
comparison to HCV-negative serum, with nearly 70% viability.
Discussion
While the deleterious effects of HIV-coinfection on HCV-
related liver disease are well documented, a number of studies
suggest that HCV may also negatively affect the course of HIV
disease. In particular, a report from the Swiss cohort study
demonstrated that HIV/HCV coinfection was associated with
increased likelihood of AIDS-defining events compared to
infection with HIV alone [11]. Furthermore, CD4 cell recovery
with HAART was slower in the presence of HCV infection.
Similar finding were reported in large cohort studies from Italy
and England [12,18]. A meta-analysis of 6216 patients from 8
trials confirmed that HAART-related immune reconstitution in
HIV/HCV coinfected patients lags behind that in patients
infected with HIV alone [19]. However, Sulkowski et al. [20] did
not find any evidence that HCV infection substantially alters the
Figure 2.  Infection of Daudi-CD4 cells with HIV.  (A) Cells
were infected with HIV (pNL4-3) and incubated with either
HCV-positive patient serum (P1-P5) or HCV-negative serum
(N1-N5) as described in Materials and Methods. Supernatant
was harvested on days 3, 6, 9, and 12 and assayed for RT
activity. Assay samples were spotted onto DEAE paper and
visualized with autoradiography. (B) RT assay results
quantified using densitometry. HIV RT activity is measured in
arbitrary units. (C) To measure apoptosis resulting from
exposure to HIV and HCV, cells were mock HIV-infected or
infected with HIV then incubated with patient serum either
positive or negative for HCV On days 3 and 5, cells were
harvested, stained with annexinV (AV) and propidium iodide
(PI), fixed, and measured for viability by flow cytometry.
Viability was determined by the percentage of cells negative for
both AV and PI. This experiment used 6 HCV-positive and 5
HCV-negative patient sera. Shown are the mean values ±
SEM.
doi: 10.1371/journal.pone.0075921.g002
risk of dying, developing AIDS, or responding immunologically
to HAART. These discrepancies could be the result of
differences among the studied populations and different
prevalence of cofactors, such as IDU. However, it should be
noted that no study so far has found a beneficial effect of HCV
on HIV progression, although a related flavivirus - GB virus C/
hepatitis G virus (GBV-C/HGV) - was credibly associated with
better survival rates [21].
Our study provides evidence for the existence of possible
biological basis of HCV-HIV interactions. HIV/HCV-coinfected
patients demonstrated less CD4+ and CD8+ T cell apoptosis
than patients infected only with HIV. This effect was largely
abolished by standard anti-HCV treatment. Since interferon
alpha demonstrates proapoptotic capabilities [22] it could have
influenced these observations. However, it should be pointed
out that the level of apoptosis correlated inversely with HCV
RNA load in serum Furthermore, the dynamics of CD19+ B
cells were reverse, as patients with double infection had higher
apoptosis than HIV-monoinfected patients, and apoptosis
decreased during antiviral treatment. The latter findings are
compatible with those reported by Toubi et al, who found that
spontaneous B cell apoptosis is increased in chronic hepatitis
C but returns to normal values in sustained responders to
antiviral treatment [23].
Figure 3.  Time course of apoptosis in Daudi-CD4+ cells
infected with HIV and incubated with either HCV-positive
or HCV-negative patient serum.  Daudi-CD4 cells were either
HIV-infected (upper row) or mock HIV-infected (lower row) and
incubated with either HCV-positive or HCV-negative patients’
sera. As additional control cells were mock HIV-infected and
incubated with FBS only (no patient serum). Shown are the
flow cytometry results from cells harvested at four different time
points following HIV (or mock) infection: Day 5 plus 8 hours
(128 hours), day 5 plus 16 hours (136 hours), day 6 plus 8
hours (152 hours), and day 6 plus 16 hours (160 hours). Each
bar shows the percentage of cells in each of four phases: 1)
viable: PI-, AV-, 2) early apoptosis: PI-, AV+, 3) late apoptosis:
PI+, AV+, 4) final cell disintegration: PI+, AV-.
doi: 10.1371/journal.pone.0075921.g003
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While HCV coinfection may inhibit HIV-related apoptosis,
HIV/HCV co-infected patients demonstrate slower CD4+ cell
recovery on HAART, than those infected with HIV only [11–13].
The reasons for this delayed CD4+ cell recovery are unclear,
but could be related to HCV replication in lyphoid cells
including CD4+ and CD34+ progenitor cells [24,25] or even to
T-cells sequestration in the liver.
In contrast to our findings, two previous cross-sectional
studies found increased lymphocyte apoptosis in HIV/HCV-
coinfected patients when compared to HIV-monoinfected
patients [26,27]. The reasons for this discrepancy are unclear;
however, in these studies HIV/HCV-coinfected patients were
overwhelmingly IDUs, whereas HIV-positive controls were not.
Thus, it cannot be excluded that it was the drug use that
affected the level of lymphocyte apoptosis. In contrast, while
our HIV/HCV-coinfected patients were mostly IDUs, at least 6
months long abstinence was a prerequisite for inclusion into
the study. Furthermore, the effect of HCV coinfection on
apoptosis was suggested by longitudinal analysis of patients
receiving antiviral therapy and by studies in vitro on cell line
dually susceptible to HCV and HIV infections. While our in vitro
cell system did not necessary mirror events occurring in vivo,
there is evidence that there are some human cell types
susceptible to infection by both viruses. In particular, native
macrophages seem to be capable of supporting both infections
and the same cell could harbor both pathogens, a least
occasionally [9,28] However, the level of HCV replication is
low, which is true for all extrahepatic sites and cell lines.
Infection of monocytes/macrophages by HCV is not
unexpected as these cells are known to be permissive to a
wide range of viruses, including some other flaviviruses [29]
Apoptosis is considered to be the major mechanism of CD4+
T-cell depletion in HIV disease. There is convincing evidence
that this are primarily the uninfected bystander cells that
succumb to apoptosis, through a process that involves
upregulation of death receptors and their ligands and
downregulation of BCL-2 family survival factors [30,31].
Moreover, apoptosis may preferentially target HIV-1 specific
CD4+ T cells, which further contributes to loss of
immunological control of HIV-1 replication [32]. While
uninfected T cells die by apoptosis, productively infected cells
remain apoptosis resistant due to modulatory effects of various
HIV proteins [30,33]. Several HIV gene products have been
reported to have both anti-apoptotic and proapoptotic activities,
presumably switching in response to the infection stage [31].
For example, Nef may prevent apoptosis of infected cell by
downregulation of CD4 and MHC class I molecules, while it
may also enhance apoptosis by upregulation of CD95-CD95L
pathway and caspase activation. Inhibition of apoptosis may be
dominant in the early phase of infection to enhance viral
replication and infectivity [34].
It could be speculated that inhibition of “bystander” apoptosis
by HCV coinfection would be beneficial in preserving the
patient’s immune response; however, a similar effect on HIV-
infected cells would be deleterious, as it would facilitate spread
and replication of HIV. In our study exposure to HCV resulted
in extended survival of HIV-infected Daudi cells and there was
a parallel increase in HIV replication. Similarly, in a study done
with Jurkat T cells engineered to express the adenovirus E1B
19K protein (a potent inhibitor of apoptosis), HIV persistence
was enhanced due to increased cell viability [35].
The mechanism behind the inhibition of HIV-related
apoptosis by HCV is unclear. Death-receptor-mediated
apoptosis plays an important role in HCV-associated liver
injury, and apoptosis of activated T-cells may contribute to
chronic infection [36]. However, in conditional transgenic mice
expressing core, E1, E2 and NS2 proteins, Fas-mediated
apoptosis of liver cells and death were reduced, probably due
to repressing the release of cytochrome c from mitochondria
and suppressing caspase-9 and -3/7 activation [37]. HCV
proteins may work in conjunction, as it was shown that HCV
core-E1-E2 transgenic mice hepatocytes underwent less
apoptosis than transgenic tissue expressing core only [38].
Another HCV gene product attributed with extensive
modulatory effects is NS5A. This protein was shown to
enhance antiapoptotic activities of the PI3K-AKT pathway
through its interaction with p85 PI3K [39], and to inhibit
apoptosis through binding to Bin1 [40] and p53 [41]. Recently,
it was also found to suppress pro-apoptotic host cell K+ channel
[42]. The issue of the effect of HCV infection on apoptosis is far
from clear as various HCV proteins were attributed both pro-
and anti-apoptotic effects when tested in cultured cells. These
discrepancies could be the effect of different experimental
conditions but also of the non-physiological overexpression of
viral proteins in in vitro systems [36].
Conclusions
We have found that HCV/HIV-coinfected patients have less
T-cell apoptosis than patients infected with HIV alone.
Likewise, HIV-infected Daudi B-cell line remained viable longer
if exposed to HCV-positive serum. These results suggest that
HCV is a molecular-level determinant in HIV disease.
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